Real-world efficacy and safety of azvudine in hospitalized older patients with COVID-19 during the omicron wave in China: A retrospective cohort study

Debates persist regarding the efficacy and safety of azvudine, particularly its real-world outcomes. This study involved patients aged ≥60 years who were admitted to 25 hospitals in mainland China with confirmed SARS-CoV-2 infection between December 1, 2022, and February 28, 2023. Efficacy outcomes were all-cause mortality during hospitalization, the proportion of patients discharged with recovery, time to nucleic acid-negative conversion (<i>T</i> <sub>NANC</sub>), time to symptom improvement (<i>T</i> <sub>SI</sub>), and time of hospital stay (<i>T</i> <sub>HS</sub>). Safety was also assessed. Among the 5884 participants identified, 1999 received azvudine, and 1999 matched controls were included after exclusion and propensity score matching. Azvudine recipients exhibited lower all-cause mortality compared with controls in the overall population (13.3% <i>vs</i>. 17.1%, RR, 0.78; 95% CI, 0.67-0.90; <i>P</i> = 0.001) and in the severe subgroup (25.7% <i>vs</i>. 33.7%; RR, 0.76; 95% CI, 0.66-0.88; <i>P</i> < 0.001). A higher proportion of patients discharged with recovery, and a shorter <i>T</i> <sub>NANC</sub> were associated with azvudine recipients, especially in the severe subgroup. The incidence of adverse events in azvudine recipients was comparable to that in the control group (2.3% <i>vs</i>. 1.7%, <i>P</i> = 0.170). In conclusion, azvudine showed efficacy and safety in older patients hospitalized with COVID-19 during the SARS-CoV-2 omicron wave in China.

Authors

Institutions

Publication Details

Journal
Acta Pharmaceutica Sinica B
Published
2024-12-12
DOI
https://doi.org/10.1016/j.apsb.2024.12.004
Citations
1
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
0.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world efficacy and safety of azvudine in hospitalized older patients with COVID-19 during the omicron wave in China: A retrospective cohort study

Deshi Dong, Lizhong Du, Xilin Du, Jia Song et al.
1 citations
Acta Pharmaceutica Sinica B
COVID-19 Clinical Research Studies
0.39
article

Real-world efficacy and safety of azvudine in hospitalized older patients with COVID-19 during the omicron wave in China: A retrospective cohort study

Deshi Dong, Lizhong Du, Xilin Du, Jia Song, Wenfang Sun, Hongliu Jiang, Xingang Li, Li Lu, Fei Zhao, Danhua Qu, Tingting Zheng, Lingbin Lu, Meiqin Zheng, Yunxin Liu, Xuguang Chen, Bolin Zhu, Yiwen Dong, H Zhan, Shilei Yang, Aixia Wang, Pengfei Jin, Guoliang Du, Jianchun Li, Hua Cheng, Wenfeng Xu, Nan Zhang, Kun Liu, Jia Liu, Li Liu, Wei Liu, Yafeng Wang, Shumin Chen, Jinli Wang, Chunxia Yang, Xu Qian, Jingjing Ma, Lihua Yang, Liyan Wan, Xin Xu, Yuanchao Zhu, Huanhuan Jiang, Yubing Zhu, Jingwei Zhu, Hangmei Liu, Xin Hu, A. Zhao, Zhiyuan Teng, Q Zhang, Xiao Li, Zinan Zhao, Yingming Zheng, Wei Zhang, Yang Jv, Dandan Wang, Hui Ma
article en
1 citations

Abstract

Debates persist regarding the efficacy and safety of azvudine, particularly its real-world outcomes. This study involved patients aged ≥60 years who were admitted to 25 hospitals in mainland China with confirmed SARS-CoV-2 infection between December 1, 2022, and February 28, 2023. Efficacy outcomes were all-cause mortality during hospitalization, the proportion of patients discharged with recovery, time to nucleic acid-negative conversion (<i>T</i> <sub>NANC</sub>), time to symptom improvement (<i>T</i> <sub>SI</sub>), and time of hospital stay (<i>T</i> <sub>HS</sub>). Safety was also assessed. Among the 5884 participants identified, 1999 received azvudine, and 1999 matched controls were included after exclusion and propensity score matching. Azvudine recipients exhibited lower all-cause mortality compared with controls in the overall population (13.3% <i>vs</i>. 17.1%, RR, 0.78; 95% CI, 0.67-0.90; <i>P</i> = 0.001) and in the severe subgroup (25.7% <i>vs</i>. 33.7%; RR, 0.76; 95% CI, 0.66-0.88; <i>P</i> < 0.001). A higher proportion of patients discharged with recovery, and a shorter <i>T</i> <sub>NANC</sub> were associated with azvudine recipients, especially in the severe subgroup. The incidence of adverse events in azvudine recipients was comparable to that in the control group (2.3% <i>vs</i>. 1.7%, <i>P</i> = 0.170). In conclusion, azvudine showed efficacy and safety in older patients hospitalized with COVID-19 during the SARS-CoV-2 omicron wave in China.

Acta Pharmaceutica Sinica BVol. 15(1)
Qiqihar University (CN), North China University of Science and Technology (CN), Guiyang Medical University (CN), Capital Medical University (CN), Dalian Medical University (CN), Nantong University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Wenzhou Medical University (CN), First Affiliated Hospital of Wenzhou Medical University (CN), China Rehabilitation Research Center (CN), Beijing Jishuitan Hospital (CN), Soochow University (CN), Affiliated Hospital of Nantong University (CN), Shunyi Hospital of Beijing Traditional Chinese Medicine Hospital (CN), Fifth Hospital of Shijiazhuang (CN), Beijing Chest Hospital (CN), Affiliated Hospital of Guizhou Medical University (CN), North China University of Science and Technology Affiliated Hospital (CN), Beijing Luhe Hospital Affiliated to Capital Medical University (CN), Changchun Obstetrics and Gynecology Hospital (CN), Second Affiliated Hospital of Soochow University (CN), Ningxia Medical University (CN), Nanyang Medical College (CN), First Affiliated Hospital of Dalian Medical University (CN), The First People's Hospital of Guiyang (CN), Beijing YouAn Hospital (CN), Beijing Friendship Hospital (CN), Beijing Ditan Hospital (CN), Beijing Chuiyangliu Hospital (CN), Qinghai Provincial Peoples Hospital (CN), First Affiliated Hospital of Soochow University (CN), Beijing Hua Xin Hospital (CN), Beijing Obstetrics and Gynecology Hospital (CN), Nanjing Medical University (CN), Qiqihar Medical University (CN)
National Health Commission of the People's Republic of China
Zero hunger
Openalex Percentile: Top 34%
COVID-19 Clinical Research Studies
0.39
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.